CHAPTER 1 ABOUT THIS PROFILE 2
Executive summary 2
Quarterly news update 2
Company introduction 2
Company sales 2
Company financials 2
Key products and competitors 3
Data sourcing 3
Sales data 3
Analyst consensus 3
CHAPTER 2 EXECUTIVE SUMMARY 4
Key findings 4
Prescription pharmaceutical sales performance, 2001-13 5
Financial performance, 2001-13 6
Daiichi Sankyo: PharmaVitae forecasts at a glance 7
Strategic insight 8
Introduction 8
Product strategic insight 8
Olmesartan franchise central to Daiichi Sankyo's future growth 8
Uncertainty regarding generic entry 9
Two scenarios for olmesartan 10
Some genericization already priced into the upside scenario 13
Effient: Daiichi Sankyo's much-needed new revenue stream 13
M&A strategic insight 15
M&A strategic insight 15
Ranbaxy acquisition 15
SWOT analysis 17
SWOT analysis 17
Strengths 17
Weaknesses 19
Opportunities 19
Threats 20
CHAPTER 3 QUARTERLY NEWS UPDATE 23
Product developments 23
Deals and alliances 24
Product deals 24
Technology deals 26
M&A activity 27
Company announcements 30
Future product milestones 34
CHAPTER 4 COMPANY INTRODUCTION 35
Key findings 35
Background 36
M&A history 36
Ranbaxy acquisition 37
Zenotech: opportunity in biopharmaceuticals 37
Current corporate structure 38
CHAPTER 5 COMPANY SALES 39
Key findings 39
Prescription pharmaceutical sales and growth rate analysis, 2001-13 40
Product analysis 42
Product analysis, 2001-07 43
Product analysis, 2007-13 46
Therapy area analysis 50
Therapy area analysis, 2001-07 51
Therapy area analysis, 2007-13 54
Therapy area focus, 2001-13 57
Geographic analysis 59
Geographic analysis, 2001-07 61
Geographic analysis, 2007-13 65
Geographic focus, 2001-13 69
Launch/core/expiry analysis 71
Explanation of launch/core/expiry analysis 71
Launch analysis, 2007-13 72
Core analysis, 2007-13 73
Expiry analysis, 2007-13 74
Launch/core/expiry configuration, 2007-13 76
Molecule type analysis 77
Molecule type analysis, 2001-07 78
Molecule type analysis, 2001-07 78
Molecule type analysis, 2007-13 80
Externalization analysis 83
Externalization analysis, 2001-07 84
Externalization analysis, 2007-13 87
CHAPTER 6 COMPANY FINANCIALS 91
Key findings 91
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2001-07 92
Financial statements, 2001-07 94
Profit and loss account, 2001-07 94
Balance sheet, 2001-07 96
Operating costs and profit analysis 98
Operating costs and profit analysis, 2001-07 99
Operating cost ratio and profit margin analysis, 2001-07 100
Operating cost ratio and profit margin analysis, 2007-13 101
Operating costs and profit analysis, 2007-13 103
Return on capital employed analysis 105
Capital employed analysis, 2001-07 106
Return on capital employed (RoCE) analysis, 2001-07 108
CHAPTER 7 KEY PRODUCTS AND COMPETITORS 111
Key findings 111
Overview 112
Cardiovascular 113
Benicar 113
Overview 113
Sales forecast 114
Benicar HCT 116
Overview 116
Sales forecast 117
Azor 119
Overview 119
Sales forecast 120
WelChol 122
Overview 122
Sales forecast 123
Mevalotin 125
Overview 125
Sales forecast 126
Hematology 128
Effient 128
Overview 128
Sales forecast 129
Infectious diseases 131
Cravit 131
Overview 131
Sales forecast 132
Endocrine, metabolic & genetic disorders 134
Rivoglitazone 134
Overview 134
Sales forecast 135
CHAPTER 8 APPENDIX 137
R&D pipeline 137
References 138
Datamonitor Reports 138
Abbreviations 138
Exchange rates 140
List of Tables
Table 1: Daiichi Sankyo - PharmaVitae forecasts at a glance 7
Table 2: Olmesartan franchise sales forecasts, 2007-13 ($m) 12
Table 3: Daiichi Sankyo key product developments, 2008 23
Table 4: Daiichi Sankyo product deals and alliances, 2008 24
Table 5: Daiichi Sankyo technology deals and alliances, 2008 26
Table 6: Daiichi Sankyo M&A activity, 2008 27
Table 7: Daiichi Sankyo company announcements, 2008 30
Table 8: Daiichi Sankyo future product milestones, 2009-11 34
Table 9: Daiichi Sankyo product portfolio overview ($m), 2001-07 43
Table 10: Daiichi Sankyo product portfolio overview ($m), 2007-13 46
Table 11: Daiichi Sankyo product portfolio overview ($m), 2001-07 51
Table 12: Daiichi Sankyo product portfolio overview ($m), 2007-13 54
Table 13: Daiichi Sankyo portfolio overview by geographic region ($m), 2001-07 61
Table 14: Daiichi Sankyo portfolio overview by geographic region ($m), 2007-13 65
Table 15: Daiichi Sankyo launch portfolio overview ($m), 2007-13 72
Table 16: Daiichi Sankyo core portfolio overview ($m), 2007-13 73
Table 17: Daiichi Sankyo expiry portfolio overview ($m), 2007-13 74
Table 18: Daiichi Sankyo portfolio overview by molecule type ($m), 2001-07 78
Table 19: Daiichi Sankyo product portfolio overview by molecule type ($m), 2007-13 80
Table 20: Daiichi Sankyo product portfolio overview by source ($m), 2001-07 84
Table 21: Daiichi Sankyo product portfolio overview by source ($m), 2007-13 87
Table 22: Total Daiichi Sankyo sales by business unit ($m), 2001-07 92
Table 23: Daiichi Sankyo profit and loss account ($m), 2001-07 94
Table 24: Daiichi Sankyo balance sheet ($m), 2001-07 96
Table 25: Daiichi Sankyo operating revenue/cost analysis ($m), 2001-07 99
Table 26: Daiichi Sankyo operating cost ratio analysis (% of total revenues), 2001-07 100
Table 27: Daiichi Sankyo operating cost ratio analysis (% of total revenues), 2007-13 101
Table 28: Daiichi Sankyo operating revenue/cost analysis ($m), 2007-13 103
Table 29: Daiichi Sankyo capital employed ($m), 2001-07 106
Table 30: Daiichi Sankyo EBIT return on capital employed ($m), 2001-07 108
Table 31: Daiichi Sankyo EBIT pre-tax return/capital employed driver analysis (%), 2001-07 109
Table 32: Key products overview 112
Table 33: Benicar: overview 113
Table 34: Benicar: sales forecast ($m), 2007-13 114
Table 35: Benicar HCT: overview 116
Table 36: Benicar HCT: sales forecast ($m), 2007-13 117
Table 37: Azor: overview 119
Table 38: Azor: sales forecast ($m), 2007-13 120
Table 39: WelChol: overview 122
Table 40: WelChol: sales forecast ($m), 2007-13 123
Table 41: Mevalotin: overview 125
Table 42: Mevalotin: sales forecast ($m), 2007-13 126
Table 43: Effient: overview 128
Table 44: Effient: sales forecast ($m), 2007-13 129
Table 45: Cravit: overview 131
Table 46: Cravit: sales forecast ($m), 2007-13 132
Table 47: Rivoglitazone: overview 134
Table 48: Rivoglitazone: sales forecast ($m), 2007-13 135
Table 49: Daiichi Sankyo's R&D pipeline (Phase I-registration) 137
Table 50: Exchange rates, 2007 140
List of Figures
Figure 1: Daiichi Sankyo prescription pharmaceutical performance, sales ($m) and growth rate (%), 2001-13 5
Figure 2: Daiichi Sankyo's financial performance ($m), 2001-13 6
Figure 3: Daiichi Sankyo: key strategic themes 8
Figure 4: The differing scenarios of olmesartan and its impact on the future of Daiichi Sankyo 11
Figure 5: Positive impact of Effient on Daiichi Sankyo's top line 14
Figure 6: Daiichi Sankyo's newest addition: Ranbaxy subsidiary 16
Figure 7: Daiichi Sankyo SWOT analysis 17
Figure 8: Current corporate structure 38
Figure 9: Daiichi Sankyo prescription pharmaceutical performance, sales ($m) and growth rate (%), 2001-13 40
Figure 10: Daiichi Sankyo key sales growth driver & resistors ($m), 2001-07 44
Figure 11: Daiichi Sankyo key sales growth drivers & resistors ($m), 2007-13 47
Figure 12: Daiichi Sankyo prescription pharmaceutical sales by therapy area ($m), 2001-13 50
Figure 13: Daiichi Sankyo prescription pharma sales by therapy area (% of total), 2001-13 57
Figure 14: Daiichi Sankyo prescription pharmaceutical sales by geographic region ($m), 2001-13 60
Figure 15: Daiichi Sankyo growth drivers and resistors by geographic region ($m), 2001-07 63
Figure 16: Daiichi Sankyo drivers and resistors by geographic region ($m), 2007-13 68
Figure 17: Daiichi Sankyo prescription pharmaceutical sales by geographic region (% of total), 2001-13 69
Figure 18: Daiichi Sankyo launch/core/expiry configuration ($m), 2007-13 76
Figure 19: Daiichi Sankyo prescription pharmaceutical sales by molecule type ($m), 2001-13 77
Figure 20: Daiichi Sankyo growth drivers and resistors by molecule type ($m), 2007-13 81
Figure 21: Daiichi Sankyo prescription pharmaceutical sales by source ($m), 2001-13 83
Figure 22: Daiichi Sankyo growth drivers and resistors by source ($m), 2001-07 85
Figure 23: Daiichi Sankyo growth drivers and resistors by source ($m), 2007-13 88
Figure 24: Daiichi Sankyo operating revenue/cost analysis ($m), 2001-13 98
Figure 25: Daiichi Sankyo operating cost ratio analysis (% of total revenues), 2001-13 102
Figure 26: Daiichi Sankyo return on capital employed, EBIT margin and capital turnover, 2001-07 105
Figure 27: Return on capital employed formula 109
